Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $7.07 billion. The enterprise value is $7.37 billion.
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 139.30 million shares outstanding. The number of shares has increased by 8.61% in one year.
| Current Share Class | 139.30M |
| Shares Outstanding | 139.30M |
| Shares Change (YoY) | +8.61% |
| Shares Change (QoQ) | +5.27% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 122.12% |
| Float | 138.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.44 |
| Forward PS | 19.57 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 65.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36
| Current Ratio | 3.36 |
| Quick Ratio | 3.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -47.70% |
| Return on Invested Capital (ROIC) | -45.76% |
| Return on Capital Employed (ROCE) | -48.14% |
| Weighted Average Cost of Capital (WACC) | 6.98% |
| Revenue Per Employee | $168,337 |
| Profits Per Employee | -$1.16M |
| Employee Count | 673 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.62% in the last 52 weeks. The beta is 0.47, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -21.62% |
| 50-Day Moving Average | 61.89 |
| 200-Day Moving Average | 69.49 |
| Relative Strength Index (RSI) | 29.60 |
| Average Volume (20 Days) | 2,097,567 |
Short Selling Information
The latest short interest is 17.93 million, so 12.87% of the outstanding shares have been sold short.
| Short Interest | 17.93M |
| Short Previous Month | 18.63M |
| Short % of Shares Out | 12.87% |
| Short % of Float | 12.93% |
| Short Ratio (days to cover) | 10.04 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $113.29 million and -$777.89 million in losses. Loss per share was -$6.02.
| Revenue | 113.29M |
| Gross Profit | -294.08M |
| Operating Income | -708.24M |
| Pretax Income | -777.89M |
| Net Income | -777.89M |
| EBITDA | -694.73M |
| EBIT | -708.24M |
| Loss Per Share | -$6.02 |
Full Income Statement Balance Sheet
The company has $1.13 billion in cash and $1.43 billion in debt, with a net cash position of -$296.84 million or -$2.13 per share.
| Cash & Cash Equivalents | 1.13B |
| Total Debt | 1.43B |
| Net Cash | -296.84M |
| Net Cash Per Share | -$2.13 |
| Equity (Book Value) | -321.17M |
| Book Value Per Share | -2.31 |
| Working Capital | 833.73M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$571.97 million and capital expenditures -$16.61 million, giving a free cash flow of -$588.58 million.
| Operating Cash Flow | -571.97M |
| Capital Expenditures | -16.61M |
| Depreciation & Amortization | 13.52M |
| Net Borrowing | -15.96M |
| Free Cash Flow | -588.58M |
| FCF Per Share | -$4.23 |
Full Cash Flow Statement Margins
| Gross Margin | -259.58% |
| Operating Margin | -625.15% |
| Pretax Margin | -686.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.61% |
| Shareholder Yield | -8.61% |
| Earnings Yield | -11.85% |
| FCF Yield | -8.32% |
Analyst Forecast
The average price target for Cytokinetics is $109.42, which is 115.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $109.42 |
| Price Target Difference | 115.48% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 119.94% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -1.33 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.33 |
| Piotroski F-Score | 4 |